Following the acquisition, Richter is reportedly planning to integrate the Finox team focusing on female fertility as part of its growing specialized women’s healthcare business. “Finox’s senior management and commercial teams have extensive experience in women’s reproductive medicine from leading international pharmaceutical companies,” Richter said in the press statement.
With the acquisition, Richter obtains global rights for BEMFOLA® – a biosimilar r-hFSH, which stimulates the ovaries in order to treat infertility – for which marketing authorization was already granted in EU in May 2014 and is currently sold in more than 20 countries, the press statement noted.
The rights for r-hFSH containing product to be registered by the U.S. Food and Drug Administration and the distribution in the United States were excluded from the transaction, the statement added.
According to Richter, benefits of the purchase complements the company’s existing Women’s Healthcare franchise, further strengthens Richter’s presence in main European markets, and increases Richter’s exposure to biosimilar markets.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
